MedTrace Logo

Intravenous Lidocaine to Reduce ED50 for Propofol Administered Using Target Controlled Infusion (TCI) During Gastroscopy

NCT06143410 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-04-24

No results posted yet for this study

Summary

The goal of this prospective, interventionnal clinical trial is to assess if intravenous administration of linisol reduce the ED50 of propofol when administered using Target Controlled Infusion (TCI) during gastroscopy in healthy patients (ASA 1 and 2 patients).

Prior to propofol sedation, participants will receive either an intravenous bolus of linisol (1.5 mg/kg) = treated group or placebo = control group.

Conditions

  • Diagnostic Gastroscopy

Interventions

DRUG

Lidocaine 2% Injectable Solution

administration of a bolus of lidocaine 1.5 mg/kg

DRUG

Saline administration as placebo

administration of a bolus of saline solution as a placebo

DRUG

Propofol injection

Sedation by total intravenous administration (TIVA) of propofol using target controlled infusion (TCI)

PROCEDURE

gastroscopy

esogastroduodenoscopy

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Céline Boudart, PhD · Erasme hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-08
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06143410 on ClinicalTrials.gov